The Efficiency Paradox of Modern Exercise Science: Decoding the Longitudinal Impact of Vigorous Intensity on Mortality and Chronic Disease Risk
As the initial momentum of 2026 begins to wane, millions of individuals who committed to New Year’s resolutions are encountering the perennial challenge of exercise adherence: the perceived lack of…
Lifelong Exposure to Low LDL Cholesterol and the Risk of Dementia Analyzing the Impact of Lipid-Lowering Genetic Variants on Cognitive Health
The human brain is a biological marvel of lipid architecture, serving as the most cholesterol-dense organ in the body. While the brain represents a mere 2% of total body weight,…
Scientific Consensus and the Seed Oil Debate Layne Norton and Peter Attia Analyze Evidence-Based Nutrition and Cardiometabolic Health
In a recent and highly anticipated episode of the medical and longevity-focused podcast The Drive, host Dr. Peter Attia engaged in an in-depth technical discussion with nutrition scientist and professional…
Beyond Plaque Rupture: Comprehensive Study Identifies Non-Atherosclerotic Pathologies as Primary Cause of Myocardial Infarction in Younger Women
For decades, the clinical and public understanding of a myocardial infarction (MI), or heart attack, has been dominated by a single narrative: the rupture of an atherosclerotic plaque. In this…
Neuroscientist Lisa Mosconi Outlines New Framework for Addressing Alzheimer’s Risk in Women During Landmark Discussion on Longevity and Brain Health
The understanding of Alzheimer’s disease is undergoing a radical shift as researchers move away from viewing the condition solely as a disease of the elderly and toward a model that…
Metformin misses the mark?
The pursuit of pharmaceutical interventions to mitigate the physiological decline associated with aging has long centered on metformin, a biguanide class medication traditionally indicated for the management of type 2…
The Evolving Frontier of GLP-1 Receptor Agonists From Diabetes Management to the Potential Prevention of Neurodegenerative Diseases
The pharmaceutical landscape has been fundamentally altered by the emergence of Glucagon-like peptide-1 receptor agonists (GLP-1-RAs), a class of medications that includes blockbuster drugs such as semaglutide (marketed as Ozempic…
Metformin misses the mark?
The medical community has long scrutinized metformin, a biguanide antihyperglycemic agent primarily indicated for type 2 diabetes, for its potential secondary benefits in the realm of healthy aging and longevity.…













